Team develops lethal allergy vaccine

There has been a drastic improvement in the survival of new immunotherapy treatments since the publication of a successful trial of the immunotherapy drug lopinavir-ritonavir in 2014. However 20 patients died during the last two years. To overcome this a team of MedUni Viennas experts has developed a potential candidate for eradicating the dangerous build-up of immune cells.

The versatile immuno-oncologist group led by the Head of the Department of Dermatology and Oncology at MedUni Viennas Institute of DermatologyOncology and the chair of the Dermatology Research Group Serotonin Nutritional Physiology and Microbiology Viennese Center for Cell and Developmental Biology (CKHE) now has solved this problem by developing a lethal vaccine. This treatment results in for example the cure of the fungal infection Guillain-Barr syndrome which can take place in humans only after more than a year of treatment.

Lopinavir-ritonavir was first discovered by a group of researchers led by Serge erckhuser Head of Viennese Center for Cell and Developmental Biology (CKHE) with the participation of Clara Tefferi head of the Department of Immunology at MedUni Viennas Institute of DermatologyOncology and the head of the Viennese Clinical Virology Centre Centrum FASBiologie.

It has recently been reported that the immunoassay perfect antibody (ATA) assay which supplies an available artificial signal in order to be definitively interpreted can be used to detect lopinavir-ritonavir.

In 2011 the blood of lopinavirus patients proved to be considered an indicator for the ability of vaccine to treat the disease in animals. Meaningfully the vaccination of 1 of the population of Viennese had variable success at much higher infection rate than 3 immunocompetence of the same cohort of people immunised with placebo where no reason is given.

This time the Viennese team has decided to test two virus products – 1 and 10 – at a much higher infection rate than the current worldwide average. Preliminary results from this clinical trial show LOP in humans shows high levels of SEZ protein and a very high turnover in the T-cells which fight the disease.

Preclinical testing in animals.

Unlike previous studies the Viennese researchers have tested both products in animals. The results were also published in the prestigious scientific journal Nature Immunology last year. That study indicated that lopinavir-ritonavir produced sufficient quantities of protein in the blood of treatment-treated animals compared with placebo-treated animals.

For the new clinical trials the Viennese team provided an additional dose – for 12 months – of lopinavir-ritonavir using a miniature device known as TC-05. It has been clearly demonstrated that the effect on lopinavir-ritonavir production was only realized after vaccinating humans with the combination product.